No Detail Found!

Use of eculizumab in thrombotic microangiopathy associated with hematopoietic stem cell transplantation

Author(s)
Sinan Demircioglu Department of Hematology, Meram Faculty of Medicine, Necmettin Erbakan University,Konya,Turkey
Ali Dogan Department of Hematology, Faculty of Medicine, Van Yuzuncu Y1l University,Van,Turkey
Cengiz Demir Department of Hematology, Faculty of Medicine, Van Yuzuncu Y1l University,Van,Turkey
Abstract
Thrombotic microangiopathy (TMA) associated with hematopoietic stem cell transplantation, remains a di cult complication due to its high mortality rate, lack of standardised diagnostic criteria, and limited treatment options. Although the etiology of the disease is not clear, medications, radiotherapy, graft-versus-host disease (GVHD), angioinvasive fungal, viral infections and complement activation have been implicated. Agents such as therapeutic plasma exchange (TPE), steroids, rituximab, de brotide, eculizumab are used in its treatment. The use of treatments such as TPE, steroids, de brotide, and rituximab did not yield satisfactory results in transplant-associated TMA (TA-TMA). Recent studies have reported successful results with eculizumab in the treatment of TA-TMA. As there is no standard dose for eculizumab in the treatment of TA-TMA, doses used in atypical hemolytic uremic syndrome (aHUS) were administered. In this paper, we present a case that was unresponsive to TPE and steroids, but which was successfully treated with eculizumab.
Publication Details
Page(s) 1359-1361
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 11, Year: 2021

Request the full text from PASTIC

Keywords
Acute myeloid leukemia, Thrombotic microangiopathy, Apheresis, Eculizumab, Stem cell transplantation
0

Citations

0

Downloads

111

Views